Obesity is the most serious public health challenge of the 21st century, with at least 2.8 million people dying each year as a result of being overweight or obese. With diabetes, heart disease and certain cancers linked to being overweight, the need to understand eating behavior and promote healthier lifestyles is vital.
The University of Liverpool is home to the Kissileff Laboratory, the UK’s largest academic facility dedicated to the study of human ingestive behavior, and a renowned team of academic staff who are at the forefront of research into the behavioural and psychological processes that govern the way we eat.
We work with external organisations on a range of projects from developing new foods to improve diet and health, to testing treatments for obesity, to examining the effect of advertising on child eating behaviour.
Our well-equipped labs allow us to study eating behavior and appetite expression from the bench to analysis of the whole person.
The Kissileff Eating Behaviour Laboratory is a purpose-built suite of rooms comprising:
- Research kitchen
- Testing and assessment rooms
- Participant lounge
- Bioassay lab for collecting, preparing and storing biological samples (blood, urine, saliva, faecal matter, skin and cheek swabs)
- Social eating lab with audiovisual suite and participant observation room connected by a ‘one-way’ mirror
- Media analysis suite
- iDXA for analysing whole body composition.
Why work with us?
- Well equipped: access to the UK’s largest academic eating behaviour laboratory, complete with the latest equipment including iDXA for whole body composition analysis
- Broad expertise: renowned academics who collaborate and consult across disciplines including psychology, public health and behavioural science
- Strong connections: part of the Liverpool Obesity Research Network with links to people and facilities, giving us easy access to clinical populations for studies
- Industry links: excellent track record of working with external organisations including Coca Cola, Danone, Unilever and GlaxoSmithKline.